Scierosing Cholangitis

Authors: Ruchi Sharma, MD¹; Mary S. Stone, MD²; Donald E. Macfarlane, MD, PhD³; Gopala Koneru, MD⁴

Organizations/Affiliations: ¹Department of Internal Medicine, University of Iowa Hospital and Carver College of Medicine ²Department of Dermatology and Pathology, University of Iowa Hospital and Carver College of Medicine ³Department of Hematology, Oncology and Bone Marrow Transplantation, University of Iowa Hospital and Carver College of Medicine ⁴Department of Gastroenterology and Hepatology, University of Iowa Hospital and Carver College of Medicine

Introduction

Erdheim-Chester disease (ECD) is a rare histiocytosis recently recognized A 64-year-old male presented with fatigue, pruritis, 15-pound as a neoplasm due to discovery of weight loss, bilirubin 1.8 mg/dL (0.3-1), and alkaline MAPK pathway mutations. ECD can phosphatase (ALP) 1671 IU/L (44-147). MRCP showed involve multiple systems, but hepatic multifocal, short segment dilation of intrahepatic ducts only. involvement is exceedingly rare. Liver biopsy showed periportal and focal bridging fibrosis suggesting primary sclerosing cholangitis (PSC). Anti-smooth muscle, anti-mitochondrial, antineutrophil cytoplasmic antibodies (ANCA) were negative, IgG subclasses normal. A month later he developed emesis, weakness, and leukocytosis. CT scan showed perinephric and periaortic soft tissue stranding suggestive of ECD. ¹⁸FDG PET/CT showed a 2.1x2.9 cm highly FDG avid mediastinal mass, follicular lymphoma on biopsy. He improved with antibiotics but Figure 1A: CT abdomen showing perinephric soft returned after a few days with emesis, leukocytosis, and tissue stranding and encasement(white arrow). bilirubin 10.7 mg/dL, ALP 1277 IU/L. CT scan showed periaortic soft-tissue progressive perinephric and (Figure1A). Endoscopic retrograde encasement cholangiopancreatography showed a common bile duct (CBD) stricture and non-filling right hepatic duct. Despite CBD stenting bilirubin continued to rise. He now had molluscum like skin lesions which on biopsy revealed dermal proliferation of CD68+, Factor XIIIa+, CD1a- histiocytes and multiple giant cells characteristic of ECD (Figure1B). Targeted therapy with BRAF or MEK pathway inhibitors was considered though there was concern that he may be too sick Figure 1B: extensive histiocytic infiltration (majority to receive these. Patient and family opted for comfort care. of cells) seen on skin biopsy and multiple giant cells





(blue arrows).

Erdheim-Chester Disease Associated With Aggressive

Case Description



Discussion

Despite symptoms, cholestatic liver function and biopsy suggestive of PSC, several factors make us question this diagnosis; such as lack of inflammatory bowel disease or positive ANCA which are seen in 60-80% patients with PSC. PSC is usually indolent, time from diagnosis to death or liver transplant generally being 10-12 years. This patient was transitioned to hospice within 6 months. This makes us suspect hepatic involvement with ECD or an overlap syndrome, or that PSC associated with ECD runs a much more aggressive course. Though liver and CBD biopsies did not show ECD, it is not unusual for biopsy findings in ECD to be obscured by non-specific fibrosis. We want to highlight that a negative biopsy should not delay diagnosis of ECD if imaging is indicative, especially as effective therapy is now available.

